

Index

a

- abbreviated new drug applications (ANDAs) 84
- abrasion 270, 392
- acetonitrile, ternary systems 120, 121
- acidity constants (pK_a) 32
- active pharmaceutical ingredient (API)
 - 84, 134, 228, 329
 - amorphous API 464–466
 - and co-crystal formers 244
 - critical quality attributes (CQAs) 306
 - dosage forms
 - inhalation 36
 - transdermal route 36–37
 - drug products
 - injectables 34–35
 - solid dosage forms 35–36
 - good manufacturing practice (GMP) 84–85
 - needle-like morphology 243
 - nonstoichiometric hydrates 255
 - solid form control for low-dose drug 451–453
 - solid form selection 447
 - solid state properties 306
- adefovir dipivoxil (AD) 366
- agglomeration 292–295, 386–390
- allotropism 93
- amorphization
 - of α -glucose 334
 - dry milling of crystalline drugs 356
 - during freeze-drying 359–364
 - tolbutamide 343
- amorphization methods
 - high energy milling, crystalline materials 228
 - mechanical path 227
 - thermal quenching 228
 - thermal route 227
- amorphous compounds 192, 194, 464
- amorphous/crystalline solids
 - solid state, rheology 192
 - structural aspects 190
- amorphous indomethacin 356
- amorphous solid dispersions (ASD) 220, 228, 344
- amorphous stability
 - conventional glass formation 201
 - liquid/crystal interface energy 203
 - molecular mobility 202
- amorphous stability, prediction
 - confinement and size effect 204
 - heterogeneous nucleation 204
 - polymorphism 203
- amorphous state
 - amorphous stability
 - kinetic crystallization, nucleation and growth 200
 - metastability, crystallization 198
 - crystal melting vs. glass softening 192
 - fragile molecules, stabilization 190
 - glassy and amorphous compounds 194
 - negative aspects 189
 - order and disorder
 - crystallinity 193

amorphous state (*contd.*)
 small or disordered perfect crystals 193
 poorly soluble compounds 190
 anti-plastification 223
 area under the curve (AUC) 68
 armodafinil 479–481
 Arrhenius diagrams (Log (τ)) 219
 aspirin 470
 atomic force microscopy (AFM) 74
 atorvastatin calcium 351, 476
 automated direct nucleation control (ANDC) 315

b

β -cyclodextrin 175
 β process 218
 binary systems, polymorphism
 mixed crystals
 one component 102–105
 one stable one metastable, full miscibility 111–112
 solid to solid transitions limitations 112–114
 two isostructural monotropic forms 113
 two stable one component, full miscibility 105–107
 two stable one component, limited miscibility 108–109
 no mixed crystals
 one component 98–100
 one stable, two form monotropism 100
 stoichiometric compound 100–102
 three enantiotropic 100
 two enantiotropic, one form monotropism 100
 bioavailability 11–14, 356–357
 biopharmaceutical classification system (BCS) 12
 biopharmaceutics 11–14
 biopharmaceutics risk assessment roadmap (BioRAM) 12
 bitopertin 453
 chemical structure 453

energy-temperature diagram 453, 454
 solubility in ethanol 454, 455
 Bragg law 193, 416
 Bravais–Friedel–Donnay–Harker model 144
 brivaracetam (BRV) 64
 brucine dihydrate 166

c

calorimetric signature, T_g 205, 206
 Cambridge Crystallographic Data Centre (CCDC) 134
 Cambridge Structural Database (CSD) 64, 65, 161
 carbamazepine (CBZ) 67
 DSC thermograms 433
 TG-FTIR 439
 carbamazepine polymorphs 401, 402, 405
 carboxylic acids, for co-crystal formation 244
 casopitant mesylate crystallization, statistical DoE
 control space 313
 design space 312, 313
 Design-Expert® software platform 310
 fractional factorial studies 310
 Fusion PRO® software platform 310
 power/volume values 310
 process parameters 308
 QbD approach 307
 response surface methodology 310
 scoping study 308
 ^{13}C CP/MAS ssNMR spectra 425
 center for drug evaluation and research (CDER) 14
 cimetidine 470
 clarithromycin 403
 classical nucleation theory (CNT) 264–266
 Clausius–Clapeyron equation 95
 clopidogrel bisulfate 408
 co-amorphization 365
 co-crystal eutectic constants (Keu) 66

- co-crystals 3, 61
 - description 350
 - EMA and FDA classification 460
 - examples 350
 - liquid-assisted/solvent-drop grinding 351
- cohesion/adhesion phenomena, in
 - powders 388
- co-grinding 350–351
- combined liquid- and solid-state *in-situ* crystallization (CLASSIC) NMR 428
- co-milling 350–351
- compactibility 406
- compressibility 406
- compression 342–345
- contact methods 383
- conventional glass formation 201
- cooperative rearrangement regions (CRR) 213
- critical material attributes (CMA) 4
- critical process parameters (CPP) 4
- critical quality attributes (CQAs) 4, 306
- cross polarization (CP) 425
- crystal energy landscapes
 - interpretation of 145
 - tazofelone 146
- crystal form
 - novelty of 472
 - obviousness 472
 - patent history 477
 - patent litigations, arguments for and against obviousness in 478
 - serendipity, role of 475
- crystal growth 290–291
- crystal melting vs. glass softening 192
- crystal structure
 - comparison 141
 - composition solvate/hydrate stoichiometry 439–443
 - properties
 - solubilities, morphologies, mechanical properties 143
 - spectroscopic 143
 - single-crystal X-ray diffraction 415
 - solid-state nuclear magnetic resonance spectroscopy (ssNMR) 424–430
 - vibrational spectroscopy 417–424
- crystalline hydrates, dehydration of 229
- crystalline mesophase formation 357–358
- crystallinity 54, 193
- crystallization
 - behaviours 150
 - during freeze-drying 359
 - indomethacin 344
 - mannitol 361, 364
 - from melt method 249
 - sorbitol 358
 - trehalose 359
- crystallization process 20–21
 - development and impurities 453–456
- modeling concepts for
 - agglomeration 292–295
 - crystal growth 290–291
 - model-based optimization 290, 295
 - parameter estimation 290
 - population balance equations 286–289
 - solvent-mediated polymorph transformation 291
- scale-up 305
 - API critical quality attributes 306
 - cooling method 325
 - crystallization processes 318–324
 - disappearing polymorphs 324
 - heat transfer 325–326
 - mass transfer 316–318
 - metastable zone width, mixing impact of 324
 - mixing optimization 316
 - mixing process parameter 316
 - polymorph control methods 324–325
 - problems 305

crystallization process (*contd.*)
 process analytical technology
 (PAT), for polymorph control
 314–316
 statistical design of experiments
 306–307
 VisiMix[®] calculations 316–322
 curcumin polymorphs 403

d

dehydration 338–341
 raffinose pentahydrate 341
 trehalose dihydrate 341
 deliquescence 117–119
 density functional theory (DFT-D)
 calculations 177, 429
 design of experiments (DoE) 6
 desmotropy 93
 developability classification system
 (DCS) 12
 differential scanning calorimetry (DSC)
 77, 431–436
 dihydrate polymorphs 177
 dispersion forces 137
 disproportionation 43–44
 microscopic solvation 44
 pH_{max} 43
 solid surface pH 44
 dissociation constant
 acids and bases 38
 equilibrium constant 38
 ionization constant 37
 pK_{a} 39–40
 weak electrolytes 37
 dissolution profile, of MBP 465
 distributed multipole (DMA) 137
 dosage forms
 inhalation 36
 transdermal route 36–37
 drug discovery 7
 drug product intermediate (DPI) 84
 drug products (DP) 10
 control strategy for 448
 injectables 34–35
 life cycle 52–53
 solid dosage forms 35–36
 drug research and development 471

drug substance (DS) 3, 10–11
 drug product intermediate 34
 high soluble 35
 dry granulation 336
 dry powder inhalation (DPI) 36
 dynamic heterogeneity 213
 dynamic nuclear polarization (DNP)
 429, 430
 dynamic vapor sorption (DVS) 431,
 440–443

e

efflorescence 115, 117–119
 enantiotropic polymorphs 100
 enantiotropy 96, 97
 energy balances 288
 energy landscape 208
 equilibrium constant 38
 equilibrium states 92

f

failure mode effect analysis (FMEA) 5,
 307
 famotidine, packing arrangement of
 403
 felodipine 231
 fenoprofen calcium dihydrate 358
 fictive temperature 216
 fluid bed granulation 336
 fluid dynamics 288
 F3 mnemonic 10
 Focused Beam Reflectance Method
 (FBRM[®]) 314
 Fourier transform infrared spectroscopy
 (FT-IR) 70
 fracture 392
 fragile compounds 213
 fragile liquids 211, 213
 fragility 209
 freeze-drying 229, 347–349
 amorphization and crystallization
 359
 freeze-dried formulations 347
 of indomethacin solution 349
myo-inositol phase transformations
 347, 348

of paracetamol 349
 freezing aqueous solutions 345–346
 fumaric acid co-crystal 460

g

gabapentin, lactamization rates of 353, 355
 generally recognized as safe (GRAS) 61, 62, 243
 genotoxic impurities, sulfonic acid salt 459
 Gibbs free energy diagram 208
 Gibbs function 199
 Gibbs phase rule 93–94
 glass softening *vs.* crystal melting 192
 glass transition
 calorimetric signature, T_g 205, 206
 entropy crisis 207
 fragile and strong glass formers 207
 physical aging 206
 vibrations 206
 glassy amorphous state 208
 glassy compounds 194
 glutaric acid co-crystal 460
 good manufacturing practice (GMP) 84–85
 granulation process
 dry granulation 336
 fluid bed 336
 hydrate formation 337–338
 wet granulation 336, 341
 gravimetric vapor sorption (GVS) 160

h

H_2 -antagonists 470
 Havriliak–Negami function 211
 heat transfer 325–326
 Helmholtz free energy 139
 heterogeneous equilibria 95
 heterogeneous nucleation 204, 268
 heterosolvates 115
 high shear granulators 336
 high-throughput screening (HTS) 48, 252, 253
 holistic solid form control strategy 448, 449

drug product 450–451
 drug substance 449–450
 polymorph screening activities 464
 homogeneous nucleation 262–267
 hot melt extrusion (HME) 227, 229, 349–350
 hot-stage microscopy 74
 hydrate/anhydrate system, of drug substance 456–458
 hydrate crystallization 170
 hydrate dehydration 364–365
 hydrate formation 337–338, 364
 hydrate forming systems 183
 hydrates 115
 crystallization 170
 forming systems 183
 isostructural dehydrate 175
 statistics of 170
 structure and properties 174
 hydroxypropylmethylcellulose acetate succinate (HPMC-AS) 465
 hygroscopicity 54, 117–119
 behaviors, pharmaceutical solids 168
 classification 162
 moisture sorption analysis 166
 hygroscopic solids 115

i

impurity 102, 279–280, 453–456
 indomethacine 225, 344, 406
 infrared absorption spectroscopy 422
 inhalation 36
 injectables 34–35
 in-process recrystallization 358
 minimizing amorphization 359
 intramolecular hydrogen bonding 177
 in vitro DP dissolution in vivo
 bioavailability correlation (IVIVC) 11
 inverse gas chromatography (IGC) 386
 capacity factor 387
 in food industry 387
 in pharmaceutical industry 387
 physicochemical parameters 387

inverse gas chromatography (IGC)
(*contd.*)

surface amorphous content and
agglomeration 387

ionic co-crystals (ICCs) 63–65

ionizable 31

ionization constant 37

ionization, pH 39

IR spectroscopy 77

selection rules 417

vs. Raman spectroscopy 420

isomorphous desolvates 115

isothermal microcalorimetry (IMC)
436–438

j

Johari–Goldstein process (JG) 218

k

Kauzmann paradox 207

kinetic crystallization, nucleation and
growth 200

kinetic heterogeneities 214

l

lattice disorder, creation of
altered particulate and bulk
properties 352–353
chemical stability 353–356
solubility and bioavailability
enhancement 356–357

lattice energy 136

liquid-assisted/solvent-drop grinding
351

long range order (LRO) 191

low-frequency Raman spectroscopy
423

m

magic angle spinning (MAS) 78

mannitol crystallization 345, 361, 362,
364

manufacturing classification system
(MCS) 11

mass transfer 316–318

maximum absorbable dose (MAD) 13

mechanical equilibrium 91

mechanochemistry 31

melting point 54, 69–70

mesophases 3

metastable crystal forms 472

metastable equilibria 91, 107

metered dose inhalation (MDI) 36

methylene blue pentahydrate 434

methyl paraben 72

microcrystalline cellulose (MCC)

DVS curve of 442

particles 353, 354

micronized salbutamol sulfate powders
352

microprecipitated bulk powder (MBP)
465

microscopy, co-crystals 74

milling 333–336

purpose of 392

mixed solvates 115

model-based optimization, of
crystallization process 295

moisture sorption-desorption isotherms
166–168

molecular crystal powders 191
batch-to-batch variability 390–393

hydration–dehydration 393–395

milling-induced agglomeration
386–390

surface interactions and bulk
properties 395–399

molecular crystals

defects 400

hydration 401

mechanical properties 402–405

microstructural evolution 399

milling induced disorder 396

solid-state characterization 381

structural damage of 399

structure–property–response/
performance 385–386

surface characterization techniques
383

surface probing 386

molecular dynamics 137

molecular mobility
and entropy 212

- fragile and strong glass formers 210, 211
 - and instability
 - aging phenomenon 214
 - non linearity 217
 - secondary relaxations 218
 - stability, assessment 216
 - monotropy 96
 - morphology 54
 - multi-component amorphous systems
 - crystalline vs. amorphous states 220
 - mixing and stabilization 224
 - multidimensional population balance model 299
- n**
- nano-crystalline drug particle
 - generation 356
 - new active substance (NAS) 83
 - new drug applications (NDAs) 84
 - N*-hydroxyethylpyrrolidine (HEP) 37
 - noncontact methods 383
 - nonobvious invention 470
 - nonsteroid anti-inflammatory drugs (NSAIDs) 82, 177
 - nonstoichiometric compounds 100
 - nonstoichiometric solvates 115
 - Norvir® 477
 - novel invention 470
 - nucleation 204
 - characterization of 270–274
 - description 261
 - deterministic nucleation rates 270–272
 - examples 261
 - heterogeneous 268
 - homogeneous 262–267
 - secondary 261, 268–270
 - stochastic nucleation rates 272–274
 - of unstable polymorph 276
 - Nuvigil® 478
- o**
- office for pharmaceutical quality (OPQ) 14
 - Ostwald's rule of stages (OSR) 246, 247, 275–277
- p**
- paracetamol 397
 - DSC thermogram 432, 435
 - XRPD patterns 417
 - Pareto optimal solutions 297
 - paroxetine hydrochloride hemihydrate 476
 - particle adhesion 390
 - Particle Vision Measurement (PVM®) 314
 - patent systems 470
 - description 469
 - obviousness inquiry 471
 - requirements for obtaining 470
 - role in pharmaceutical industry 470
 - in United States 469
 - penicillin 470
 - perfect crystals 190
 - pharmaceutical co-crystals (PCCs)
 - analytical tools
 - microscopy 74
 - patent literature review 79
 - regulatory aspects 83–85
 - solid-state NMR 78–79
 - thermal methods 77
 - vibrational spectroscopy 77–78
 - X-ray diffraction 75–77
 - definition of 61
 - properties
 - bioavailability 69
 - dissolution rate 67–68
 - melting point 69–70
 - solubility 66–67
 - stability 70–71
 - undesired effect of 71–73
 - types
 - ionic co-crystals 63–65
 - polymorphism 65
 - salts vs. co-crystals 62–63
 - pharmaceutical crystal forms 471
 - pharmaceutical development
 - bioavailability 11–14
 - biopharmaceutics 11–14

- pharmaceutical development (*contd.*)
 - crystallization process 20–21
 - drug discovery 7–10
 - drug substance and product 10–11
 - formulation of 10, 21–22
 - physical purity determination 22–23
 - polymorphism 17–20
 - process of 8, 9
 - quality assessment 14–15
 - salt/co-crystal 16–17
 - solid state discovery 16
- pharmaceutical glasses 227
- pharmaceutical hydrates 174
- pharmaceutical ionic co-crystals (PICCs) 63
- pharmaceutical processes
 - intended phase transformations 346–351
 - unintended phase transformations 333–346
- phase-appropriate approach 447
- phase field dislocation dynamics (PFDD) theory 399
- phase transformations
 - of amlodipine besylate 338
 - amorphization 352–357
 - chemical composition, changes in 364
 - co-amorphization 365
 - co-crystal formation 366
 - crystalline mesophase formation 357–358
 - hydrate formation and dehydration 364–365
 - in-process recrystallization 358
 - intended 346–351
 - salt formation and disproportionation 366–368
 - on stress-relaxation concept 332
 - unintended 333–346
- $pH_{\max}$ 42, 43
- pH -solubility 40
- physiology based pharmacokinetic (PBPK) modeling 12
- piracetam (PIR) 64
- pK_a values 32
- plastification 223
- poly(L-lactic acid) polymorphic structure 409
- polymorphism 2, 3, 245
 - access to 97–98
 - equilibrium 91
 - mechanisms 98
 - mixed crystals
 - one component 102–105
 - one stable one metastable, full miscibility 110
 - solid to solid transitions limitations 112
 - two isostructural monotropic forms 113
 - two stable one component, full miscibility 105–107
 - two stable one component, limited miscibility 108–109
- pharmaceutical co-crystals 65
- powder compaction properties 406–409
- powder flow, impact of 401–402
- salt formation 31–33
- size reduction by milling 405–406
- with unary system 95–98
- without unary system 94–95
- polymorph prediction
 - crystal energy landscapes
 - interpretation of 145
 - tazofelone 146
 - crystal structure 140
 - comparison 141
 - properties 144
- pharmaceutical industry
 - crystal structure prediction 134
 - thermodynamic prediction 134
- relative energies, crystals
 - free energy 139
 - lattice energy 136
- polymorphs 245, 248
 - characterization and selection 253–254
- crystallization method, selection of 248
- Ostwald's rule of stages 246, 247

solvent selection 250
 surface free energy 247
 thermodynamic stability,
 non-solvated forms 248
 polymorph screen 251, 255
 economic criteria 251
 elements required 252
 ICH guidelines 251
 polymorph transformation 291–292
 population balance equations 286–288
 solution of 288–289
 powder activation 387
 powder compaction properties
 compactibility 406
 compressibility 406
 dense cluster packing 406
 polymorphism impact on 408
 slip planes and defects 406
 tabletability 406
 preferential orientation 416
 pressure-induced polymorphic
 transformations 343
 primary heterogeneous nucleation 261
 primary homogeneous nucleation 261
 process analytical technology (PAT) 6,
 289, 418
 chord length distribution 315
 data collection methodology 315
 design via control strategy 315
 FBRM[®] probe 314, 315
 Particle Vision Measurement probe
 315
 for polymorph control 314
 Raman spectroscopy 315
 processing-induced phase transitions
 330, 331
 propyphenazone 79
 pseudopolymorphs 2
 pyrithydione 79

q

quadrupolar nuclei 428
 quality by design (QbD) 3–6
 design of experiments 6
 DP CQA 4
 failure mode effect analysis 5

risk assessment 4, 5
 quality target product profile (QTPP)
 4

r

Raman fiber-optic probe 424
 Raman microscopy 421
 Raman spectroscopy 77
 advantages 419, 420
 carbamazepine 418, 419
 co-crystal former 421
 disadvantages 420
 low-frequency 423
 selection rules 417
 sensitivity 421
 transmission 422
 two-dimensional mapping technique
 420
 ranitidine hydrochloride (Zantac[®])
 408, 475
 relative energies, crystals
 free energy 139
 lattice energy 136
 risk assessment 4, 5
 ritonavir 476

s

salt formation
 active substances 33–37
 basics of 37–44
 characterization
 initial data 45
 salt formers 45–46
 disproportionation 43–44,
 366
 dissociation constant
 acids and bases 38
 equilibrium constant 38
 ionization constant 37
 p*K*_a 39–40
 weak electrolytes 37
 drug candidates 51
 drug development 32, 33
 drug's life cycle 52–53
 drug substance 49
 ionization and pH 39
 pH-solubility 40

- salt formation (*contd.*)
 - polymorphism 31–33
 - salt preparation
 - crystallization 48, 49
 - drug substance 47
 - HTS 48
 - procedures 46–49
 - solid materials 46
 - XRPD 48
 - salt selection process 53
 - sulfonic acids 53
- salt&co-crystal screening 16–17, 244
- salt formers 45–46
- salts vs. co-crystals 62–63
- salts, screening for 242, 243
- Schroeder–Van – Laar equation 99
- secondary nucleation 261, 268–270
- seeded crystallization process
 - impurity control 279–280
 - process control 277–279
 - polymorphism control 279
- seletracetam (SEL) 64
- short range order (SRO) 197
- single-crystal X-ray diffraction (SCXRD) 75, 416
- slip planes
 - description 402
 - in indomethacin crystals 407
 - in paracetamol 400
- sodium naproxen, hydration of 339
- sodium salts, solid forms of 451, 453
- solid dosage forms 35–36
- solid forms
 - attribute control 448
 - co-crystal, quality by design 458–460
 - dalcetrapib 466
 - holistic control strategy 448, 449
 - hydrate/anhydrate system, of drug substance 456
 - intrinsic control 448
 - parametric control 448
 - polymorph screening activities 460
 - procedural control 448
 - quality by design principle 448
 - screening and selection 241, 242, 447
- solid– liquid monovariant 95
- solid-state development 1–3, 15–23
- solid-state nuclear magnetic resonance (ssNMR) spectroscopy 78–79, 424–430
 - advantages 425
 - crystallization of polymorphs 427
 - disadvantages 426
 - dynamic nuclear polarization 429, 430
 - homonuclear and heteronuclear correlation experiments 427
 - in-situ* experiments 427
 - vs. solution-state NMR 424
 - spectral editing approach 425
- solid-state, rheology 191
- solubility 54, 66–67
- solubility limited absorbable dose (SLAD) 12
- solution calorimetry (SolCal) 438–439
- solvates 245, 247
 - chiral discrimination formation 121–123
 - formation and stability 248
 - hygroscopicity, deliquescence, efflorescence 117
 - identification of 245
 - isomorphous, formation of 253
 - stoichiometric vs. non-stoichiometric 116–117
- solvent-based crystallization processes 170
- solvent-mediated polymorph transformation 291
- sorption coefficient 388
- sorption isotherms 168
- sorption kinetics, microcrystalline cellulose 163
- spray-drying 229, 346–347
- statistical design of experiments 306–307
 - failure mode and effects analysis 307
 - response surface methodology 307
 - scale-independent parameters 306
 - screening matrixes 307

Kepner-Tregoe 307
 stoichiometric solvates 114
 vs. non-stoichiometric solvates
 116–117
 strong liquids 210
 Structure Activity Relationship
 (SAR) 7
 sulfamerazine 408
 sulfathiazole 405
 supersaturation control (SSC) 315
 surface characterization techniques
 practical applications and information
 383
 size scales 384
 surface energetics 390

t

tablet formation, compression pressure
 for 342
 tabletability 406
 terahertz (THz) spectroscopy 422,
 423
 terahertz pulse spectroscopy (TPS)
 422
 ternary systems
 chiral discrimination formation
 121–123
 thermal equilibrium 91
 thermal methods 77
 thermal quenching 228
 thermodynamical stable polymorph
 17
 thermodynamic properties
 differential scanning calorimetry
 431–436
 dynamic water vapor sorption
 experiments 431
 isothermal microcalorimetry (IMC)
 436–438
 solid forms 431
 solution calorimetry (SolCal)
 438–439
 thermodynamics
 allotropism 93
 chemical purity 92
 chirality 93

 components 93
 desmotropy 93
 Gibbs phase rule 93–94
 isotopic purity 92
 structural purity 92–93
 unary system/section
 with polymorphism 95–98
 without polymorphism 94–95
 water solid interactions 160
 thermogravimetric analysis (TGA) 46,
 77, 182, 439–440
 thermogravimetry-Fourier transform IR
 (TG-FTIR) 440
 thermogravimetry mass spectrometry
 (TG-MS) 252, 440
 time-temperature-transformation
 (TTT) 200, 201
 Tool, Narayanaswamy, Moynihan
 (TNM) expression 218
 tosylate salts 459
 transdermal route 36–37
 transmission Raman spectroscopy
 422
 triethanolammonium modafinate
 (TMM) 122
 two-step nucleation theory (2-SNT)
 263, 264, 266–267

u

unary system/section
 with polymorphism 95–98
 polymorphs access 97–98
 polymorphs mechanisms 98
 without polymorphism 94–95

v

van der Waals interaction 137
 vapor-liquid equilibria 94
 vemurafenib 356, 357
 chemical structure 464
 transformation scheme 465
 USP4 dissolution profiles 466
 validated XRPD method 466
 vibrational spectroscopy 77–78,
 417–424
 VisiMix[®] calculations 316–322

Vogel–Fulcher–Tamman equation
(VFT) 212

W

water–solid interactions 160
weak electrolytes 37
wet bead-milling 356
wet drying 182
wet granulation 336, 341

X

xemilofiban 352
X-ray crystallographic methods 75
X-ray diffraction (XRD) 75–77, 195,
416–417
X-ray powder diffraction (XRPD) 46,
71, 75, 76, 78, 416